Evidence map›Paper›PMID 42598525›Full record

ArticleMolecular therapy. Oncology2026

Eradication of pre-clinical prostate tumors by a lentiviral vector-based immunotherapy.

Benjamin Vesin, Ingrid Fert, Sylvain Ciret, Laëtitia Douguet, Fanny Moncoq, Amandine Noirat, Pierre Authié, Fabien Le Chevalier, Fabien Nevo, Catherine Blanc and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Benjamin VesinPasteur-TheraVectys Joint Lab, Institut Pasteur, Université de Paris, Virology Department, 28 Rue Du Dr. Roux, 75015 Paris, France.
Ingrid FertPasteur-TheraVectys Joint Lab, Institut Pasteur, Université de Paris, Virology Department, 28 Rue Du Dr. Roux, 75015 Paris, France.
Sylvain CiretPasteur-TheraVectys Joint Lab, Institut Pasteur, Université de Paris, Virology Department, 28 Rue Du Dr. Roux, 75015 Paris, France.
Laëtitia DouguetPasteur-TheraVectys Joint Lab, Institut Pasteur, Université de Paris, Virology Department, 28 Rue Du Dr. Roux, 75015 Paris, France.
Fanny MoncoqPasteur-TheraVectys Joint Lab, Institut Pasteur, Université de Paris, Virology Department, 28 Rue Du Dr. Roux, 75015 Paris, France.
Amandine NoiratPasteur-TheraVectys Joint Lab, Institut Pasteur, Université de Paris, Virology Department, 28 Rue Du Dr. Roux, 75015 Paris, France.
Pierre AuthiéPasteur-TheraVectys Joint Lab, Institut Pasteur, Université de Paris, Virology Department, 28 Rue Du Dr. Roux, 75015 Paris, France.
Fabien Le ChevalierPasteur-TheraVectys Joint Lab, Institut Pasteur, Université de Paris, Virology Department, 28 Rue Du Dr. Roux, 75015 Paris, France.
Fabien NevoPasteur-TheraVectys Joint Lab, Institut Pasteur, Université de Paris, Virology Department, 28 Rue Du Dr. Roux, 75015 Paris, France.
Catherine BlancPasteur-TheraVectys Joint Lab, Institut Pasteur, Université de Paris, Virology Department, 28 Rue Du Dr. Roux, 75015 Paris, France.
Kirill NemirovPasteur-TheraVectys Joint Lab, Institut Pasteur, Université de Paris, Virology Department, 28 Rue Du Dr. Roux, 75015 Paris, France.
Laleh MajlessiPasteur-TheraVectys Joint Lab, Institut Pasteur, Université de Paris, Virology Department, 28 Rue Du Dr. Roux, 75015 Paris, France.
Pierre CharneauPasteur-TheraVectys Joint Lab, Institut Pasteur, Université de Paris, Virology Department, 28 Rue Du Dr. Roux, 75015 Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer kills ≈350,000 yearly. While localized cases have 99% five-year survival, metastatic prostate cancer is hard to treat, with few options for tumors resistant to androgen deprivation. To leverage the immune system to fight prostate cancer, we developed a non-integrative lentiviral vector, namely "Lenti-PROST-02", which encodes clusters of T cell immunodominant regions of human prostatic acid phosphatase and prostate-specific antigen. Immunotherapy with Lenti-PROST-02 in a preclinical virulent prostate tumor model resulted in complete tumor eradication in vast majority of the treated animals. This antitumor effect was concomitant with induction of poly-functional CD8

Indexed as

immune memoryimmuno-oncotherapyinflammationlentiviral vectorsprostate-associated antigenprostate cancersprostatic acid phosphataset cell vaccinestumor microenvironmenttumor relapse

Identifiers

PMID42598525
PMCPMC13471139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.